ABSTRACT
Molybdenum disulfide ( MoS2) quantum dots ( QDs) were synthesized using one-step hydrothermal method with an acceptable fluorescence property. Based on the quenching effect between doxycycline hyclate ( DOX) and MoS2QDs, a fluorescence method for detection of DOX was established. The interaction between MoS2QDs and DOX was discussed with a final proposal of the static quenching mechanism. A good linear correlation for detection of DOX using fluorescenct MoS2QDs was obtained in the concentration range of 0. 86-55. 40 μg/mL, with a detection limit of 0. 023 μg/mL (S/N=3). The fabricated sensor was applied to the detection of DOX in real samples with RSDs of less than 5% . The relative error of determination results of MoS2QDs method compared with HPLC was from -4. 5% to 0. 8% and -4. 6% to 2. 8% for DOX tablet and DOX spiked milk, respectively. The fluorescence detection of DOX in real sample using MoS2QDs was simple, rapid and reliable.
ABSTRACT
<p><b>OBJECTIVE</b>To observe the effect of Chuanhuang No.1 Recipe (CHR) on renal function and micro-inflammation in phase 3 chronic kidney disease (CKD) patients.</p><p><b>METHODS</b>Totally 60 phase 3 CKD patients were randomly assigned to the treatment group (treated by CHR) and the control group (treated by Losartan Potassium), 30 in each group. All patients received basic treatment. Patients in the treatment group took CHR decoction, 400 mL each time, one dose per day, while those in the control group took Losartan Potassium, 50-100 mg per day. All medication lasted for 24 weeks. Changes of serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), serum uric acid (UA), 24 h urinary protein excretion (24 h U-pro), urinary microalbumin (U-Alb), high-sensitivity C-reactive protein (hs-CRP), serum tumor necrosis factor (TNF)-alpha, and serum IL-6 were detected and compared before and after treatment. Efficacy was also compared.</p><p><b>RESULTS</b>Compared with before treatment, SCr and BUN significantly decreased in the treatment group (P<0.05, P<0.01); eGFR in- creased (P<0.05). Only UA obviously decreased in the control group (P<0.05), but with no obvious change in SCr, BUN, or eGFR. Compared with before treatment, 24 h U-pro decreased after treatment in the treatment group (P<0.05), but with less decreased level when compared with the control group. U- Alb was also significantly decreased in the control group (P<0.01). There was statistical difference in 24 h U-pro and U-Alb between the two groups after treatment (P<0.05). Compared with before treatment, hs-CRP obviously decreased after treatment in the two groups, but serum levels of TNF-alpha and IL-6 obviously decreased only in the treatment group (P<0.05). The total effective rate was obviously higher in the treatment group than in the control group (70.00% vs. 43.33%, P<0.01).</p><p><b>CONCLUSION</b>CHR could efficiently improve the renal function of phase 3 CKD patients and alleviate the micro-inflammation.</p>